secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196505
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.02, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion acquires Exscientia in stock deal; director Burrell resigns; Q2 results reported
--------------------------------------------------------------------------------

- Recursion to acquire Exscientia via UK scheme of arrangement; Exscientia shareholders get 0.7729 Recursion shares per share.
- Termination fees: Exscientia pays $6.88M if it accepts a superior proposal; Recursion pays $58.77M if it walks.
- Terry-Ann Burrell resigns from board effective Aug 12, 2024; Zachary Bogue appointed Audit Committee Chair.
- Q2 2024 financial results announced; specific figures not provided in this filing but refer to press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000119312524196505/0001193125-24-196505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000119312524196505/d856792d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer